MedTrace Logo

Comparison of Valsartan With Amlodipine in Hypertensive Patients With Glucose Intolerance

NCT00129233 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1150

Last updated 2013-05-01

No results posted yet for this study

Summary

Various guidelines recommended angiotensin converting enzyme (ACE) inhibitors or angiotensin Ⅱ receptor-1 blockers (ARBs) for hypertensive patients with diabetes on the basis of the cardiac- and reno-protective effects of these drugs. However, these recommendations could not be extrapolated to Japanese patients, because Japan has been known as a country with a low incidence of coronary artery disease and a high incidence of cerebrovascular disease. Furthermore, calcium channel blockers (CCBs) also were protective against renal function as well as ACE inhibitors in Japanese diabetic hypertensive patients. This study will test whether ARBs or CCBs are superior in treating Japanese diabetic hypertensive patients.

Conditions

Interventions

DRUG

Valsartan

valsartan 80 to 160 mg daily

DRUG

Amlodipine

Amlodipine 5 to 10 mg daily.

Sponsors & Collaborators

  • Nagoya University

    lead OTHER

Principal Investigators

  • Toyoaki Murohara, MD, PhD · Department of Cardiology, Nagoya University Graduate School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2010-07-31
Completion
2013-04-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00129233 on ClinicalTrials.gov